Therapies aimed at changing patients' genes are poised for approval in the US and one has already reached the market in Europe, writes Erika Check Hayden at Nature News, but they come with a hefty price tag.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.